| Dr Nickolas Daniel Juliano, MD | |
|
1 Diamond Hill Rd, Bensley Pavilion, Berkeley Heights, NJ 07922-2104 | |
| (908) 277-8700 | |
| (908) 277-8993 |
| Full Name | Dr Nickolas Daniel Juliano |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 24 Years |
| Location | 1 Diamond Hill Rd, Berkeley Heights, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114192101 | NPI | - | NPPES |
| 25928 | Medicaid | OR | |
| 082165027 | Other | OR | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0011X | Internal Medicine - Interventional Cardiology | 25MA09303500 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Overlook Medical Center | Summit, NJ | Hospital |
| Morristown Medical Center | Morristown, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cardiovascular Health Consultants, P.a. | 8325934706 | 106 |
| Summit Medical Group Pa | 5395642276 | 1253 |
News Archive
Aventyn Inc., an innovative provider of secure connected clinical information processing solutions, today announced the introduction of healthKrypt™, patent pending technology for securing health information and trusted transaction processing. This announcement was made jointly at HIMMS in Atlanta, GA and RSA2010 in San Francisco, CA.
A Walgreen official maintained a defense of the split even as rival drug stores have ramped up their marketing efforts to attract Express Scripts customers.
A group of Italian researchers headed by Prof. Giovanni Fava (University of Bologna) has published a multicenter investigation on demoralization in the setting of medical disease. Demoralization was defined according to diagnostic criteria encompassing unpleasant, distressing feelings of personal failure and inadequacies, with a loss of continuity in the sense of sequence between past and future.
Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.
› Verified 1 days ago
| Entity Name | Summit Medical Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942254347 PECOS PAC ID: 5395642276 Enrollment ID: O20031218000011 |
News Archive
Aventyn Inc., an innovative provider of secure connected clinical information processing solutions, today announced the introduction of healthKrypt™, patent pending technology for securing health information and trusted transaction processing. This announcement was made jointly at HIMMS in Atlanta, GA and RSA2010 in San Francisco, CA.
A Walgreen official maintained a defense of the split even as rival drug stores have ramped up their marketing efforts to attract Express Scripts customers.
A group of Italian researchers headed by Prof. Giovanni Fava (University of Bologna) has published a multicenter investigation on demoralization in the setting of medical disease. Demoralization was defined according to diagnostic criteria encompassing unpleasant, distressing feelings of personal failure and inadequacies, with a loss of continuity in the sense of sequence between past and future.
Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.
› Verified 1 days ago
| Entity Name | Cardiovascular Health Consultants, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437291739 PECOS PAC ID: 8325934706 Enrollment ID: O20040224000028 |
News Archive
Aventyn Inc., an innovative provider of secure connected clinical information processing solutions, today announced the introduction of healthKrypt™, patent pending technology for securing health information and trusted transaction processing. This announcement was made jointly at HIMMS in Atlanta, GA and RSA2010 in San Francisco, CA.
A Walgreen official maintained a defense of the split even as rival drug stores have ramped up their marketing efforts to attract Express Scripts customers.
A group of Italian researchers headed by Prof. Giovanni Fava (University of Bologna) has published a multicenter investigation on demoralization in the setting of medical disease. Demoralization was defined according to diagnostic criteria encompassing unpleasant, distressing feelings of personal failure and inadequacies, with a loss of continuity in the sense of sequence between past and future.
Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nickolas Daniel Juliano, MD 1 Diamond Hill Rd, Bensley Pavilion, Berkeley Heights, NJ 07922-2104 Ph: (908) 277-8700 | Dr Nickolas Daniel Juliano, MD 1 Diamond Hill Rd, Bensley Pavilion, Berkeley Heights, NJ 07922-2104 Ph: (908) 277-8700 |
News Archive
Aventyn Inc., an innovative provider of secure connected clinical information processing solutions, today announced the introduction of healthKrypt™, patent pending technology for securing health information and trusted transaction processing. This announcement was made jointly at HIMMS in Atlanta, GA and RSA2010 in San Francisco, CA.
A Walgreen official maintained a defense of the split even as rival drug stores have ramped up their marketing efforts to attract Express Scripts customers.
A group of Italian researchers headed by Prof. Giovanni Fava (University of Bologna) has published a multicenter investigation on demoralization in the setting of medical disease. Demoralization was defined according to diagnostic criteria encompassing unpleasant, distressing feelings of personal failure and inadequacies, with a loss of continuity in the sense of sequence between past and future.
Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.
› Verified 1 days ago
Silpa Gadiraju, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Diamond Hill Rd, Berkeley Heights, NJ 07922 Phone: 908-273-4300 Fax: 908-673-7336 | |
Dr. John H Dokko, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Diamond Hill Rd, Summit Medical Group, Berkeley Heights, NJ 07922 Phone: 908-273-4300 Fax: 908-277-8808 | |
Dr. Lawrence J Nastro, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1 Diamond Hill Rd, Summit Medical Group, Berkeley Heights, NJ 07922 Phone: 908-273-4300 Fax: 908-277-8825 | |
Christopher M Boni, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Diamond Hill Rd, Berkeley Heights, NJ 07922 Phone: 908-277-8683 Fax: 908-608-2378 | |
Dr. Jeffrey Okun, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Diamond Hill Rd, Berkeley Heights, NJ 07922 Phone: 908-273-4300 | |
Dr. Michele Elkins, M.D Internal Medicine Medicare: Medicare Enrolled Practice Location: 1060 Mountain Ave, Berkeley Heights, NJ 07922 Phone: 908-464-6740 | |
Shruti P Dhorajia, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Diamond Hill Rd, Berkeley Heights, NJ 07922 Phone: 908-273-4300 |